In two randomized, double-blind ascending-dose trials in healthy adults, a single subcutaneous dose raised mean plasma growth hormone 2- to 10-fold for 6 days or more. Mean IGF-I rose 1.5- to 3-fold for 9 to 11 days.
Teichman SL et al., J Clin Endocrinol Metab 2006




